haploidentical donor lymphocyte infusion

This cellular immunotherapy approach, developed by Brown University (specifically Rhode Island Hospital and The Miriam Hospital), involves the infusion of haploidentical donor peripheral blood cells for the treatment of refractory hematological malignancies. The therapy consists of infusing a specific dose of 1-2×10^8 CD3+ T-cells per kilogram along with CD34+ cells from a family member donor. Notably, this treatment is administered without preconditioning chemotherapy (non-myeloablative approach), distinguishing it from traditional hematopoietic stem cell transplantation. The primary mechanism of action is the induction of a potent graft-versus-tumor (GVT) immune response. This is achieved through the purposeful rejection of the donor cells by the host's immune system, which triggers a systemic immune reaction and cytokine release syndrome (CRS) that breaks host tumor tolerance. The therapy has been evaluated in Phase I/II trials for aggressive lymphomas and acute leukemias.

Other names

haplo-DLIcellular immunotherapy